Correction to: SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c—Translating Evidence into Practice

Diabetes Therapy - Tập 10 - Trang 1623-1624 - 2019
Amar Ali1, Steve Bain2, Debbie Hicks3, Phillip Newland Jones4, Dipesh C. Patel5, Marc Evans6, Kevin Fernando7, June James8, Nicola Milne9, Adie Viljoen10, John Wilding11
1Oakenhurst Medical Practice, Blackburn, UK
2Diabetes Research Unit Cymru, Swansea University, Swansea, UK
3Medicus Health Partners, Enfield, UK
4University Hospitals Southampton NHS Foundation Trust, Southampton, UK
5Department of Diabetes and Endocrinology, Division of Medicine, University College London, London, UK
6Department of Diabetes, University Hospital Llandough, Llandough, UK
7North Berwick Health Centre, North Berwick, UK
8University Hospitals of Leicester NHS Trust, Leicester, UK
9CODES (Community Diabetes Education and Support), Manchester University NHS Foundation Trust, Manchester, UK
10Department of Metabolic Medicine/Chemical Pathology, Lister Hospital, Stevenage, UK
11Obesity and Endocrinology Research, University of Liverpool, Liverpool, UK

Tóm tắt

In the original publication, Table 2 note was incorrectly published as “SGLT2i therapies may be initiated in people with eGFR 60 mL/min/1.73 m2. Individuals already treated with canagliflozin or empagliflozin who demonstrate renal decline may continue treatment until eGFR reaches < 45 mL/min/1.73 m2”.

Thông tin
Thông tin xuất bản

Diabetes Therapy

Tập 10

1623-1624

Thông tin tác giả